Abstract: Methods and uses for enhancing or restoring the antitumor response, such as the antitumor immune mediated by immune checkpoint inhibitors, in cancer patients, are described. These methods are based on the administration of castalagin or analogs thereof, and are particularly useful for the treatment of tumors resistant to immunotherapy such as immune checkpoint inhibitor therapy.

Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Abstract: The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated with Clostridium difficile infection.

Abstract: The present invention relates to inositol derivatives covalently modified with one, two or three solubility functions, particularly polyethylene glycol moieties, for use in therapy or prevention of conditions related to pathological calcium crystallization, such as cardiovascular calcifications, nephrocalcinosis, calcinosis cutis, chondrocalcinosis and kidney stones.

Abstract: The present invention relates to inositol bisthiophosphates-tetrakissulfates, particularly for use in treating symptoms associated with Clostridium difficile infection.

Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO32?, OPSO22? or OSO3?; R1 is a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by Clostridium difficile.

Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO32?, OPSO22? or OSO3?; R1 is a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by Clostridium difficile.

Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.

Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.

Abstract: The technical field of this invention is automated oligosaccharide synthesizers. There is a need in this field for more efficient oligosaccharide synthesizers. For example, the present invention is an apparatus for solid phase oligosaccharide synthesis, which includes a reaction vessel for holding a reaction mixture, such that the reaction vessel is equipped with a temperature control system, a donor vessel for holding a saccharide donor; an activation vessel for holding activator, a pump operably connected to a fluidic valve; an additional fluidic valve connected to the activation vessel, to the first fluidic valve via a first fluid line, and to the reaction vessel via a second fluid line, such that the activator or saccharide donor can be delivered via the second fluidic valve into the first fluid line and then through the second fluid line into the reaction vessel.